SEARCH

SEARCH BY CITATION

References

  • 1
    Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill. 1995;21032159 (2139–2141).
  • 2
    Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20 year study. Clin Biochem 1989; 22:223229.MEDLINE
  • 3
    Pimstone NR, Gandhi S, Mukerji S. Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1987; 316:390393.MEDLINE
  • 4
    Gorchein A, Chong SKF, Mowat AP. Oral activated charcoal in protoporphyria with liver damage. Br J Clin Pharmacol 27:390393.
  • 5
    Pimstone NR, Mukerji S, Chow H, Goldstein L. Oral charcoal therapy for protoporphyric cirrhosis [Abstract]. Hepatology 1986; 6:287A.
  • 6
    Sarkany RPE, Cox TM. Autosomal recessive erythropoietic protoporphyria: a syndrome of severe photosensitivity and liver failure. Q J Med 1995; 88:541549.
  • 7
    Rufenacht UB, Gouya L, Schneider-Yin X, Puy H, Schafer BW, Aquaron R, Nordmann Y, et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 1998; 62:13411352.MEDLINE
  • 8
    Bloomer JR. Pathogenesis and therapy of liver disease in protoporphyria. Yale J Biol Med 1979; 52:3948.MEDLINE